Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 458 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07281924RecruitingPhase 1/Phase 2
Combination Treatment for Melanoma Spread to Liver
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
Madison, WisconsinAges 18 years+ - NCT07276386RecruitingPhase 2
Combination therapy for metastatic uveal melanoma
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Tampa, FloridaAges 18 years+ - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT07223411Recruiting
Opdualag vs. cemiplimab/fianlimab for melanoma
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT04576429Recruiting
Tracking immune changes in melanoma patients on immunotherapy
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
Boulogne-BillancourtAges 18 years+ - NCT07206017Recruiting
Chicory root fiber for melanoma patients after surgery
This study tests whether adding a high-fiber chicory root supplement to your diet can help people after melanoma surgery. Researchers want to see if it improves your immune system and gut health to prevent the cancer from coming back.
Groningen, Provincie GroningenAges 18 years+ - NCT07203391RecruitingPhase 1
Tebentafusp and roginolisib for uveal melanoma
This trial tests a combination of two drugs, tebentafusp and roginolisib, for people with uveal melanoma that has spread or can't be removed. It aims to improve how long the immune system stays active against the cancer.
Sydney, New South WalesAges 18 years+ - NCT06952400Recruiting
Melanoma genetics study in Taiwan
This study looks at genetic changes in melanoma tumors to better understand the disease. It may help find the best treatments for different stages of melanoma.
Taipei, Taiwan/TaipeiAges 18 years+ - NCT07138222Recruiting
Immune therapy and fertility in women and men with melanoma
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Sydney, New South WalesAges 18–60 - NCT07112170Recruiting
Radiation to slow melanoma growth after initial treatment
This study tests whether giving precise radiation to a limited number of growing spots can help control melanoma that has spread but is otherwise stable on immunotherapy or targeted therapy. You may join if you have up to 10 growing spots outside the brain that can be safely treated with focused radiation.
Toronto, OntarioAges 18 years+ - NCT07099430RecruitingPhase 1/Phase 2
Study of LBL-024 alone or with LBL-007 or toripalimab for advanced melanoma
This trial tests a new drug, LBL-024, either by itself or combined with another drug (LBL-007 or toripalimab) in people with advanced melanoma. The goal is to see if these combinations can shrink tumors or slow cancer growth.
Fuzhou, FujianAges 18 years+ - NCT07086105RecruitingPhase 1
Study of Adze1.C for advanced melanoma
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Southport, QueenslandAges 18 years+ - NCT07068074RecruitingPhase 3
Comparing less invasive surgery to standard care for older adults with early-stage melanoma
This trial compares less invasive procedures with the current standard treatment for early-stage melanoma in adults 75 and older. The goal is to find out if these less invasive options work just as well and help patients recover better.
Birmingham, AlabamaAges 75 years+ - NCT07049276Recruiting
Lymph node surgery for melanoma with immunotherapy
This trial tests if a specific type of lymph node surgery, combined with a short course of immunotherapy (medicines that help your immune system fight cancer), works better for melanoma that has spread to nearby lymph nodes. It's for people whose melanoma can be removed and who are healthy enough for treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07050940Recruiting
Adding a gut supplement to immunotherapy for advanced melanoma
This trial tests whether adding a postbiotic (a gut-health supplement) to a standard immunotherapy called anti-PD-1 makes it work better for people with advanced melanoma that hasn't been treated yet. It may help shrink tumors or slow the cancer's growth.
Bari, BAAges 18 years+ - NCT06970236Recruiting
Strength training for eye melanoma survivors
This trial tests whether a high intensity resistance (strength) training program can help people who have been treated for choroidal melanoma (an eye cancer) with plaque brachytherapy. The goal is to improve muscle strength and overall health after cancer treatment.
Valencia, SpainAges 18 years+ - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT07031830Recruiting
Physical activity program for advanced melanoma patients
This trial tests whether an adapted physical activity program can help patients with advanced melanoma who are receiving immunotherapy or targeted therapy. It aims to support overall well-being during treatment.
RouenAges 18 years+ - NCT07015190RecruitingPhase 3
Darovasertib before surgery for eye melanoma
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT06994208Recruiting
Melanoma study for adults under 40
This study looks at the characteristics of melanoma in people younger than 40. It may help doctors understand how this cancer affects younger adults.
Genoa, LiguriaAges 18–39 - NCT06985056Recruiting
Exercise to reduce symptoms in melanoma patients
This trial tests if a supervised exercise program can help reduce symptoms like fatigue and improve well-being in people with advanced melanoma who are already on immunotherapy or targeted therapy. You would visit the study hospital for training sessions and check-ups.
EssenAges 18 years+ - NCT06961006RecruitingPhase 2
Study of an experimental vaccine plus pembrolizumab for melanoma
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
Springdale, ArkansasAges 18 years+
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 458 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.